Novo’s Drug Ingredient Could Do More Than Weight Loss:
Initial reading notes that the glucose regulating drug potential of Novo Nordisk’s main ingredient may extend beyond weight loss, pending late-stage results
Amgen MariTide weight loss: Sustains 2-year results in
Amgen MariTide weight loss results show promising long-term weight management support, indicating potential as a sustainable obesity treatment option pending
Novo Nordisk Metsera Takeover: Mike Doustdar Eyes Future
Despite losing out in the Novo Nordisk Metsera takeover, the company remains committed to pursuing strategic acquisitions to strengthen its position in the